WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, J. K.
Right arrow Articles by Crawley, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, J. K.
Right arrow Articles by Crawley, J. N.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 13, 5119-5125, Copyright © 1993 by Society for Neuroscience

ARTICLE

Intraseptal galanin potentiates scopolamine impairment of delayed nonmatching to sample

JK Robinson and JN Crawley
Section on Behavioral Neuropharmacology, National Institute of Mental Health, Bethesda, Maryland 20892.

Galanin coexists with ACh in the basal forebrain and medial septal region. The present study investigated the interactions of the muscarinic receptor antagonist scopolamine and the neuropeptide galanin on an operant spatial delayed non-matching to sample task (DNMTS) in rats. Scopolamine administered both intraperitoneally and microinjected into the medial septum impaired performance on DNMTS. Galanin administered alone into the medial septum did not disrupt DNMTS, but potentiated the disruptive effects of intraperitoneal administered scopolamine. These findings raise the possibility that endogenous galanin may exacerbate cognitive impairments associated with forebrain cholinergic deficits.


This article has been cited by other articles:


Home page
 Behav Cogn Neurosci RevHome page
J. K. Robinson
Galanin and Cognition
Behav Cogn Neurosci Rev, December 1, 2004; 3(4): 222 - 242.
[Abstract] [PDF]

Home page
 Mol. Interv.Home page
S. E. Counts, S. E. Perez, S. D. Ginsberg, S. de Lacalle, and E. J. Mufson
Galanin in Alzheimer Disease
Mol. Interv., May 1, 2003; 3(3): 137 - 156.
[Abstract] [Full Text] [PDF]


-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-